Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PGDM1400, PGT121, and VRC07-523LS in HIV-uninfected and HIV-infected Adults
NCT03205917Phase 1Completed
- Sponsor
- International AIDS Vaccine Initiative
- Start
- Oct 2017
- Primary completion
- Apr 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PGDM1400LS in human immunodeficiency virus infection (HIV) (8 arms), sponsored by International AIDS Vaccine Initiative. Primary endpoints: Safety and tolerability, Elimination half-life (t1/2) and 5 more. Started Oct 2017; status: completed.
02
Drugs
PGDM1400LS
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03205917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03205917.